malign
brain
tumor
continu
repres
devast
diagnosi
real
chanc
cure
despit
increas
list
potenti
salvag
therapi
standardofcar
patient
chang
decad
immunotherapi
seen
excit
option
potenti
offer
specif
long
last
tumor
clearanc
gold
standard
immunotherapi
develop
tumorspecif
cell
respons
potenti
tumor
clearanc
immunolog
memori
mani
advanc
made
field
immunotherapi
therapi
seen
true
success
mani
principl
use
develop
immunotherapi
tumor
peripher
organ
appli
brain
tumor
immunotherapi
immunespeci
natur
brain
call
question
whether
approach
appropri
recent
result
experi
requir
rethink
current
dogma
perhap
cell
respons
suffici
organ
immunolog
uniqu
brain
examin
previous
elucid
principl
brain
immunespeci
statu
known
immunolog
prefer
gener
discuss
experiment
address
failur
current
therapi
despit
grow
interest
immunotherapi
brain
tumor
prognosi
diseas
remain
grim
approxim
malign
primari
brain
tumor
diagnos
year
unit
state
malign
glioma
account
major
case
although
brain
tumor
account
major
cancer
diagnos
repres
disproportion
high
number
cancer
death
patient
grade
iv
glioma
refer
glioblastoma
multiform
gbm
median
surviv
month
dismal
prognosi
due
part
lack
therapeut
option
patient
diagnos
tumor
current
standardofcar
gbm
includ
surgic
resect
radiotherapi
chemotherapi
uniqu
natur
brain
pose
challeng
develop
addit
therapeut
option
blood
brain
barrier
bbb
exclud
certain
drug
make
pharmaceut
develop
tumor
unus
addit
due
invas
natur
tumor
surgic
resect
entir
tumor
proven
imposs
tumor
cell
abl
infiltr
normal
brain
tissu
even
extrem
case
full
hemispherectomi
perform
tumor
ultim
recur
contralater
hemispher
current
chemotherapi
choic
temozolomid
tmz
primarili
due
abil
penetr
bbb
combin
tmz
radiotherapi
effect
extend
surviv
radiotherapi
alon
result
progressionfre
surviv
two
year
compar
radiotherapi
alon
howev
progressionfre
surviv
tmzradiotherapi
combin
still
dismal
even
therapi
success
extend
surviv
side
effect
devast
current
method
use
result
damag
surround
normal
tissu
caus
longterm
neurolog
problem
especi
problemat
pediatr
patient
whose
develop
nervou
system
particularli
suscept
bystand
effect
immunotherapi
attract
option
brain
tumor
offer
potenti
specif
endur
tumor
clearanc
complex
natur
immun
respons
central
nervou
system
cn
pose
uniqu
challeng
field
brain
tumor
immunotherapi
gener
tumorspecif
cell
respons
focu
tumor
immunotherapi
approach
well
reason
result
disappoint
produc
minim
respons
patient
evid
cure
one
possibl
explan
limit
success
current
immunotherapi
protocol
failur
target
compon
immun
system
examin
immunolog
statu
cn
potenti
elicit
altern
immun
respons
tumor
may
provid
explan
suboptim
respons
offer
anoth
mean
tumor
elimin
brain
tumor
immunotherapi
especi
challeng
due
special
relationship
cn
immun
system
idea
immun
privileg
state
cn
develop
earli
studi
analyz
differenti
reject
transplant
tissu
cn
versu
peripheri
tumor
readili
reject
peripher
organ
protect
immunolog
reject
brain
parenchyma
suggest
lack
immunolog
respons
appar
recent
refut
lack
lymphat
vessel
brain
presenc
bbb
support
notion
immunolog
steril
site
addit
studi
demonstr
transplant
tissu
could
readili
reject
cn
host
previous
reject
graft
peripheri
suggest
activ
lymphocyt
abl
migrat
cn
howev
data
suggest
pauciti
lymphat
drainag
cn
prevent
reject
transplant
nonimmun
host
work
demonstr
graft
implant
brain
result
acceler
immunereject
graft
peripheri
suggest
cn
inde
capabl
elicit
immun
respons
outsid
cn
data
collect
suggest
affer
effer
arm
immun
system
intact
cn
contrari
initi
hypothes
recent
studi
examin
efflux
protein
cn
found
fluid
carri
potenti
antigen
leav
brain
enter
blood
drain
ipsilater
cervic
lymph
node
prefer
cervic
lymph
node
preferenti
drainag
cn
cervic
lymph
node
make
import
site
brain
tumor
immunolog
vaccin
near
site
appeal
prime
cervic
lymph
node
could
boost
endogen
antigen
present
take
advantag
exist
proxim
bia
brain
prior
studi
detail
cervic
lymph
node
cn
respons
antigen
great
detail
previou
theori
immun
privileg
statu
disput
new
concept
neuroimmunolog
emerg
immunespeci
natur
cn
take
account
mani
differ
immun
respons
cn
compar
peripher
organ
cervic
lymph
node
predispos
induc
immun
respons
preferenti
activ
humor
immun
respons
expens
cytotox
lymphocyt
ctl
respons
although
cell
cervic
lymph
node
respond
antigen
undergo
rapid
prolifer
direct
ctl
activ
observ
ctl
suppress
brain
like
due
cn
product
transform
growth
factor
tgf
suppress
ctl
activ
render
respons
ineffect
addit
cerebr
spinal
fluid
csf
drain
cervic
lymph
node
contain
possibl
gener
polar
respons
moreov
viral
infect
immun
special
site
lung
brain
activ
selfregul
produc
antiinflammatori
cytokin
potenti
minim
tissu
destruct
physic
natur
brain
permit
much
swell
inflamm
without
catastroph
consequ
reason
assum
tight
regul
inflammatori
immun
respons
serv
limit
damag
signific
organ
consid
restraint
immunotherapi
tumor
within
cn
requir
overcom
signific
hurdl
varieti
approach
design
stimul
tumorreact
immun
respons
examin
multitud
tumor
type
despit
complex
natur
cn
immunolog
immunotherapi
treatment
brain
tumor
still
activ
area
research
fda
approv
cancer
immunotherapi
proveng
sipuleucelt
prostat
cancer
ipilimumab
metastat
melanoma
provid
initi
proofof
concept
effect
antitumor
immun
respons
recent
therapi
target
demonstr
excit
result
fda
approv
nivolumab
pembrolizumab
bolster
concept
immunotherapi
viabl
treatment
option
cancer
patient
howev
shortag
success
immunotherapi
larg
underscor
difficulti
field
whole
face
emphas
pauciti
phase
iii
clinic
trial
brain
tumor
immunotherapi
deliveri
mab
use
target
known
tumor
associ
antigen
human
epiderm
growth
factor
overexpress
approxim
breast
cancer
administr
herceptin
trastuzumab
monoclon
antibodi
shown
efficaci
posit
breast
cancer
patient
likewis
epiderm
growth
factor
receptor
variant
iii
egfrviii
common
mutat
associ
glioma
result
novel
peptid
sequenc
serv
neoantigen
present
approxim
gbm
patient
treatment
mous
model
antibodi
target
egfrviii
result
tumor
regress
similar
therapi
enter
clinic
trial
passiv
immunotherapi
approach
lack
breadth
coverag
immunolog
memori
without
defin
neoantigen
everi
individu
tumor
therapi
fail
access
mani
patient
addit
heterogen
within
tumor
allow
immun
evas
absenc
multipl
target
act
success
field
melanoma
immunotherapi
tumor
infiltr
lymphocyt
til
expand
ex
vivo
readminist
patient
upon
suffici
prolifer
act
brain
tumor
use
lymphocyt
isol
peripher
blood
tumor
attempt
sever
clinic
trial
disappoint
result
focu
act
progress
test
genet
engin
autolog
cell
express
chimer
antigen
receptor
car
design
target
specif
tumor
antigen
target
clinic
trial
acut
lymphoblast
leukemia
show
remark
success
build
success
research
engin
car
cell
specif
epha
egfrviii
success
mous
model
led
human
clinic
trial
egfrviii
specif
car
therapi
similar
mab
type
therapi
benefit
individu
whose
tumor
express
specif
protein
car
cell
specif
identif
addit
antigen
target
allow
applic
greater
pool
patient
ipilimumab
yervoy
human
mab
cytotox
lymphocyt
antigen
regulatori
receptor
upregul
activ
cell
receiv
fda
approv
treatment
metastat
melanoma
compet
ligat
effect
block
product
prolifer
prevent
bind
ipilimumab
allow
sustain
signal
occur
without
inhibit
effect
remov
brake
immun
respons
clinic
trial
mani
patient
saw
increas
progressionfre
surviv
rare
complet
respons
howev
major
patient
also
develop
sever
autoimmun
complic
fda
approv
ipilimumab
restimul
field
immunotherapi
addit
checkpoint
inhibitor
investig
potenti
clinic
use
brain
tumor
like
program
death
pd
receptor
pathway
emerg
potenti
target
immunotherapi
express
activ
cell
bind
one
ligand
result
decreas
cell
activ
express
tumor
believ
promot
immun
evas
express
note
sever
type
tumor
includ
glioma
sever
mous
glioma
model
demonstr
efficaci
use
mab
either
therapi
enter
clinic
trial
brain
tumor
use
immun
modulatori
agent
cancer
treatment
rapidli
incorpor
preclin
immunotherapi
model
block
allow
potenti
antitumor
respons
nonspecif
manner
addit
mani
immun
modul
promis
target
follow
tcrmhc
engag
ligat
sever
addit
costimulatori
molecul
upregul
surfac
apc
cell
addit
costimulatori
molecul
includ
member
tumor
necrosi
factor
receptor
tnfr
famili
glucocorticoidinduc
tnfr
gitr
sever
approach
use
activ
costimulatori
signal
pathway
includ
agonist
mab
ligand
fusion
protein
correspond
ligand
fuse
immunoglobulin
protein
system
deliveri
vivo
manipul
costimulatori
molecul
attempt
anim
model
variou
diseas
tumor
immunotherapi
may
benefit
enhanc
costimulatori
signal
control
autoimmuneinflammatori
diseas
may
achiev
inhibit
signal
vaccin
make
largest
categori
immunotherapi
brain
tumor
howev
clinic
success
difficult
achiev
despit
varieti
approach
taken
vaccin
requir
tumor
antigen
form
whole
tumor
tumor
lysat
tumor
peptid
combin
adjuv
promot
appropri
antigen
present
prime
mous
human
studi
shown
favor
result
result
proven
effect
gener
cure
overcom
potenti
lack
antigen
present
dendrit
cell
dc
vaccin
pursu
well
dc
isol
patient
puls
tumor
lysat
tumor
peptid
tumor
mrna
whole
tumor
cell
readminist
patient
dc
vaccin
account
major
ongo
immunotherapi
relat
clinic
trial
brain
tumor
clinic
trial
well
toler
patient
shown
promis
sign
immun
respons
correl
radiograph
respons
modest
improv
overal
surviv
due
constraint
associ
grow
suffici
autolog
tumor
therapi
well
potenti
autoimmun
condit
induc
inclus
whole
tumor
cell
contain
normal
selfprotein
consider
effort
identifi
gliomaassoci
antigen
gaa
develop
synthet
peptid
vaccin
base
antigen
synthet
peptid
use
vaccin
administ
adjuv
done
common
mutat
egfrviii
clinic
studi
show
promis
sign
efficaci
howev
patient
lost
egfrviii
express
upon
recurr
data
suggest
immunoedit
work
indic
need
target
multipl
antigen
vaccin
avoid
immun
evas
multipl
gaa
sinc
identifi
synthet
peptid
use
puls
dc
gbm
vaccin
demonstr
immunolog
respons
modest
effect
clinic
outcom
major
peptid
mhc
irestrict
epitop
gener
intent
stimul
cell
respons
tumor
approach
exclud
cell
activ
incorpor
addit
immun
cell
respons
multipl
trial
shown
modest
success
howev
clinic
data
exist
phase
ii
trial
await
phase
iii
clinic
data
due
small
number
patient
earli
phase
clinic
trial
mani
studi
scale
show
statist
clinic
respons
consequ
mani
studi
use
biomark
cell
expans
ex
vivo
ctl
activ
delayedtyp
hypersensit
dth
respons
evalu
success
immun
despit
multipl
paper
indic
activ
respons
vaccin
none
therapi
move
past
phase
iii
clinic
trial
demonstr
cure
patient
although
possibl
reason
clinic
failur
vaccin
numer
overemphasi
cell
stimul
may
factor
hinder
progress
therapeut
efficaci
investig
vaccin
consist
autolog
brain
tumor
lysat
mix
cpgcontain
oligonucleotid
orthotop
mous
model
gbm
reveal
therapi
elicit
initi
cell
prime
respons
gener
insuffici
tumor
clearanc
addit
costimulatori
molecul
fuse
immunoglobulin
fc
protein
gener
robust
immun
respons
capabl
complet
tumor
clearanc
anim
treat
importantli
therapi
abl
gener
immunolog
memori
tumor
demonstr
complet
rapid
tumor
reject
upon
rechalleng
surviv
anim
investig
reveal
respons
gener
depend
cell
b
cell
nk
cell
interest
observ
massiv
invas
granulocyt
tumor
follow
therapi
analysi
reveal
popul
present
anim
receiv
exhibit
suppress
capabl
ex
vivo
test
suggest
neutrophil
myeloidderiv
suppressor
cell
mdsc
strike
result
reveal
mechan
tumor
reject
independ
cell
deplet
posit
cell
use
knockout
mice
alter
therapeut
outcom
light
current
dogma
surround
cell
cancer
immunotherapi
result
surpris
suggest
immun
cell
popul
consid
design
new
cancer
immunotherapi
anoth
import
aspect
result
multilay
approach
tumor
kill
involv
cell
innat
adapt
immun
system
highlight
complex
success
immunolog
respons
cancer
although
ctl
respons
consid
benchmark
therapeut
efficaci
becom
appreci
immun
cell
popul
play
equal
import
role
tumor
model
patient
focu
cell
central
immun
cell
tumor
clearanc
well
reason
cell
possess
abil
directli
kill
tumor
cell
present
tumor
antigen
via
mhc
howev
number
limit
approach
mani
cancer
sever
cancer
includ
gbm
downregul
mhc
express
evidenc
absenc
mhc
express
gbm
cell
invad
normal
brain
tissu
cell
left
surgic
resect
critic
target
immunotherapi
absenc
mhc
cell
unabl
recogn
cognat
antigen
target
cell
render
ineffect
tumor
cell
interferon
ifn
increas
mhc
express
varieti
tumor
cell
howev
mani
barrier
must
overcom
gener
success
immun
respons
gbm
discuss
immun
statu
cn
provid
signific
hurdl
gener
effect
ctl
respons
despit
immun
suppress
cell
respons
mani
immun
cell
cn
addit
mani
cell
type
possess
antitumor
properti
varieti
tumor
helper
function
cell
necessari
provid
crucial
cue
surround
cell
gener
orchestr
immun
respons
tumor
pathogen
type
respons
gener
cell
critic
efficaci
respons
emphasi
cell
bia
consid
ideal
gener
antitumor
cell
approach
sever
limit
includ
downregul
mhc
surfac
infiltr
brain
tumor
cell
dampen
cytokin
milieu
cn
sever
report
counter
import
respons
provid
evid
divers
mechan
tumor
reject
independ
cell
cell
describ
effici
tumor
reject
cell
addit
indirect
mechan
kill
cell
known
evid
cytotox
cell
particularli
viral
infect
model
cell
convent
identifi
ctl
promot
cell
humor
respons
promot
cell
identif
addit
subtyp
eg
regulatori
cell
ongo
classif
special
function
cell
open
possibl
vari
complex
respons
tumor
previous
appreci
addit
cell
necessari
initi
mainten
cell
respons
absenc
signal
result
progress
loss
activ
time
lead
blunt
antitumor
respons
histor
mani
cancer
vaccin
act
protocol
focus
mhc
irestrict
epitop
exclus
transfer
cell
subsequ
data
shown
inclus
tumor
reactiv
cell
act
could
enhanc
persist
transfer
cell
addit
vaccin
mhc
iirestrict
epitop
common
glioma
mutat
isocitr
dehydrogenas
type
success
mous
model
cell
b
cell
depend
regulatori
cell
treg
subset
cell
capac
neg
regul
immun
respons
maintain
homeostasi
prevent
uncontrol
immun
respons
autoimmun
accumul
treg
commonli
observ
glioma
increas
proport
infiltr
treg
correl
poor
outcom
tumorsecret
cytokin
respons
recruit
natur
occur
treg
ntreg
convers
th
cell
induc
treg
itreg
tumor
site
suppress
capac
cell
major
hurdl
overcom
develop
effect
antitumor
respons
deplet
treg
accomplish
chemotherapi
cyclophosphamid
although
without
potenti
side
effect
inhibit
suppressor
function
treg
achiev
costimulori
molecul
gitr
role
nk
cell
cancer
evid
name
fact
identifi
uniqu
abil
kill
tumor
without
previou
immun
sinc
multipl
modal
nk
cell
kill
tumor
virallyinfect
cell
identifi
unlik
member
innat
immun
system
presenc
nk
cell
correl
posit
outcom
cancer
patient
nk
cell
capabl
target
cell
express
mhc
upregul
certain
stress
molecul
direct
kill
target
cell
incud
releas
perforin
granzym
bind
tnfr
famili
member
secret
nitric
oxid
nk
cell
also
provid
link
innat
adapt
immun
respons
secret
cytokin
chemokin
promot
effector
cell
differenti
addit
nk
cell
also
abl
kill
antibodi
coat
target
cell
antibodi
depend
cellmedi
cytotox
adcc
fc
portion
immunoglobulin
protein
bind
fc
receptor
fcr
effector
cell
includ
nk
cell
macrophag
neutrophil
dc
mous
model
continu
provid
evid
import
nk
cell
tumor
clearanc
immunotherapi
nk
cell
infiltr
cn
human
gbm
mous
model
sever
mous
model
shown
efficaci
nk
cell
therapi
treat
brain
tumor
includ
one
studi
look
brain
metastasi
melanoma
preferenti
clearanc
nk
cell
context
knockout
anim
studi
demonstr
requir
nk
cell
effect
immunotherapi
result
indic
potenti
role
adcc
murin
model
gbm
efficaci
reduc
anim
defici
fcr
find
provid
evid
potenti
nk
cell
contribut
effect
immunotherapi
regimen
major
immunotherapeut
approach
attempt
activ
adapt
arm
immun
system
attent
given
role
cell
b
cell
larg
ignor
advantag
util
adapt
immun
respons
includ
gener
memori
antigen
specif
b
cell
encount
antigen
differenti
antibodysecret
plasma
cell
memori
b
cell
confer
protect
upon
secondari
encount
antigen
adcc
potenti
mechan
tumor
destruct
immun
system
appropri
activ
differenti
b
cell
necessari
occur
although
role
b
cell
apc
less
studi
dc
b
cell
also
present
antigen
cell
contribut
cell
activ
passiv
diffus
larg
protein
includ
immunoglobulin
brain
restrict
bbb
thu
role
antibodi
respons
efficaci
immunotherapi
brain
tumor
diminish
paradox
correl
presenc
tumorreact
antibodi
gbm
patient
surviv
observ
support
mous
model
gbm
suggest
b
cell
crucial
efficaci
immunotherapi
much
attent
given
innat
immun
cell
respons
tumor
focus
tumor
promot
immun
suppress
capac
cell
macrophag
divid
two
main
subset
convent
activ
macrophag
altern
activ
macrophag
macrophag
promot
proinflammatori
pathway
convers
tumorassoci
macrophag
tam
infiltr
tumor
site
contribut
immun
suppress
microenviron
neg
associ
patient
outcom
sever
public
rais
possibl
util
macrophag
antitumor
immun
respons
administr
agonist
antibodi
mice
human
patient
pancreat
cancer
demonstr
robust
antitumor
respons
antibodi
expect
promot
antigen
present
dc
lead
enhanc
ctl
activ
howev
studi
show
influx
tumoricid
macrophag
tumor
regress
independ
cell
microglia
brain
similar
immun
suppress
properti
brain
tumor
compos
larg
proport
brain
tumor
mani
therapeut
approach
focus
elimin
tam
altern
method
elimin
may
redirect
cell
popul
promot
tumor
elimin
inhibit
elimin
macrophag
anim
model
howev
administr
inhibitor
mous
model
gbm
elimin
tam
instead
inhibitor
chang
function
cell
abolish
immun
suppress
properti
promot
antitumor
respons
addit
studi
shown
antitumor
activ
macrophag
variou
mechan
includ
nitric
oxid
adcc
tnfrelat
apoptosi
induc
ligand
trail
induc
death
although
littl
known
role
neutrophil
context
cancer
tumorassoci
neutrophil
tan
correl
poor
prognosi
mani
cancer
patient
includ
glioma
view
potenti
target
immunotherapeut
approach
howev
much
like
macrophag
function
cell
depend
microenviron
polar
cell
protumor
antitumor
neutrophil
depend
cytokin
milieu
variabl
role
neutrophil
cancer
biolog
review
elsewher
like
macrophag
myeloidderiv
suppressor
cell
msdc
discuss
neutrophil
appear
possess
potenti
antitumor
respons
given
correct
cue
neutrophil
shown
direct
tumoricid
activ
product
reactiv
oxygen
speci
adcc
faslinduc
apoptosi
previou
observ
correl
neutrophil
infiltr
tumor
increas
surviv
rais
possibl
therapeut
reeduc
distinct
cell
popul
promot
antitumor
respons
seen
macrophag
mdsc
mdsc
constitut
heterogen
popul
immatur
myeloid
cell
termin
differenti
dc
macrophag
neutrophil
block
tumorderiv
cytokin
consequ
elev
level
circul
tumorloc
mdsc
associ
poor
prognosi
number
tumor
immun
suppressor
cell
type
larg
attribut
failur
mani
immunotherapeut
approach
strategi
ablat
cell
view
path
effect
immunotherapi
chemotherapi
reduc
number
circul
mdsc
without
signific
side
effect
convers
signal
promot
matur
reduc
immunosuppress
function
mdsc
promot
antitumor
immun
due
phenotyp
similar
mdsc
neutrophil
two
popul
difficult
distinguish
without
util
ex
vivo
suppress
assay
result
popul
resembl
mdsc
view
deleteri
effort
focus
elimin
rather
redirect
function
interest
studi
use
therapi
mous
model
melanoma
abl
significantli
inhibit
tumor
growth
intriguingli
result
independ
cell
depend
mast
cell
similarli
stimul
mast
cell
also
demonstr
antitumor
activ
murin
melanoma
model
mast
cell
abl
recruit
nk
cell
product
direct
antitumor
effect
like
innat
cell
review
mast
cell
involv
cancer
present
conflict
report
proand
antitumor
role
antitumor
properti
mast
cell
kill
tumor
directli
adcc
releas
tnf
indirectli
chemokin
recruit
cytokinemedi
modul
effector
cell
report
involv
mast
cell
tumor
biolog
immunotherapi
extens
review
elsewher
shortag
data
concern
mast
cell
glioma
howev
one
public
show
presenc
mast
cell
mous
model
glioma
well
human
patient
greater
number
mast
cell
seen
human
gbm
compar
grade
ii
glioma
suggest
tumorpromot
role
mast
cell
role
mast
cell
glioma
potenti
therapeut
alter
function
promot
tumor
clearanc
remain
seen
compil
data
suggest
convent
approach
immunotherapi
stimul
cytolyt
cell
respons
may
overli
restrict
especi
tumor
cn
cell
orchestr
immun
respons
secret
cytokin
necessari
recruit
surviv
polar
without
appropri
signal
cell
respons
diminish
time
evid
innat
immun
cell
right
condit
appropri
direct
kill
tumor
cell
therapi
includ
cell
pursu
tumor
util
multifactori
approach
immun
evasioninclud
limit
lack
antigen
present
costimul
secret
immun
suppress
cytokin
recruit
immun
suppress
cell
mdsc
tam
tan
treg
therefor
immunotherapi
offer
equal
broad
respons
broaden
approach
perhap
abl
overwhelm
tumor
tip
balanc
favor
immun
system
figur
therapi
incorpor
multipl
pathway
present
excit
opportun
stimul
multipl
cell
type
adjuv
therapi
cpg
use
stimul
dc
effici
prime
cell
also
matur
mdsc
costimulatori
molecul
gitrl
dual
role
immun
modul
addit
stimul
effector
cell
ligat
costimulatori
receptor
inhibit
treg
function
break
toler
observ
present
excit
potenti
use
combin
therapi
gener
comprehens
immun
respons
result
demonstr
cellindepend
mechan
tumor
clearanc
mous
model
gbm
suggest
cell
necessari
tumor
outsid
cn
cell
activ
respons
cn
tumor
instead
consid
along
previou
character
cn
immunolog
earlier
research
suggest
altern
mean
tumor
erad
result
promot
incorpor
addit
immun
target
immunotherapi
contribut
elucid
effect
antitumor
immun
respons
glioma
failur
current
therapi
gbm
may
due
lack
incorpor
full
immun
respons
uniqu
microenviron
brain
could
elev
import
strategi
remain
seen
altern
mechan
antitumor
respons
tumoror
locationspecif
therapeut
approach
take
account
state
tumor
microenviron
immunolog
bia
organ
resid
locationspecif
therapeut
approach
take
account
state
tumor
microenviron
immunolog
bia
organ
resid
author
declar
conflict
interest
